login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
VTV THERAPEUTICS INC- CL A (VTVT) Stock News
USA
- NASDAQ:VTVT -
US9183852048
-
Common Stock
24.24
USD
-0.68 (-2.73%)
Last: 11/5/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
VTVT Latest News, Press Relases and Analysis
All
Press Releases
a month ago - By: vTv Therapeutics Inc.
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
a month ago - By: Benzinga
- Mentions:
IONR
DFLI
CRML
AIP
...
Why AMD Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
a month ago - By: Benzinga
- Mentions:
IVA
ABP
ONMD
COSM
...
12 Health Care Stocks Moving In Monday's Pre-Market Session
2 months ago - By: vTv Therapeutics Inc.
UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
3 months ago - By: vTv Therapeutics Inc.
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
a year ago - By: InvestorPlace
VTVT Stock Earnings: vTv Therapeutics Reported Results for Q2 2024
3 months ago - By: vTv Therapeutics Inc.
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin
5 months ago - By: vTv Therapeutics Inc.
vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series
6 months ago - By: vTv Therapeutics Inc.
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
6 months ago - By: vTv Therapeutics Inc.
vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update
6 months ago - By: vTv Therapeutics Inc.
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes
1 years ago - By: BusinessInsider
VTVT Stock Earnings: vTv Therapeutics Reported Results for Q1 2024
1 years ago - By: InvestorPlace
VTVT Stock Earnings: vTv Therapeutics Reported Results for Q1 2024
8 months ago - By: vTv Therapeutics Inc.
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
8 months ago - By: vTv Therapeutics Inc.
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
a year ago - By: Cantex Pharmaceuticals, Inc.
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER
a year ago - By: vTv Therapeutics Inc.
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference
a year ago - By: vTv Therapeutics Inc.
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update
a year ago - By: InvestorPlace
- Mentions:
LUXH
LIPO
YIBO
Why Is LuxUrban Hotels (LUXH) Stock Down 12% Today?
a year ago - By: InvestorPlace
- Mentions:
LIPO
YIBO
Why Is vTv Therapeutics (VTVT) Stock Down 46% Today?
a year ago - By: InvestorPlace
- Mentions:
YIBO
LIPO
CGTX
TIVC
...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
a year ago - By: vTv Therapeutics Inc.
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
a year ago - By: vTv Therapeutics Inc.
vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
a year ago - By: Cantex Pharmaceuticals, Inc.
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
a year ago - By: Cantex Pharmaceuticals, Inc.
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER
1 years ago - By: vTv Therapeutics Inc.
vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update
2 years ago - By: Cantex Pharmaceuticals, Inc.
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
2 years ago - By: vTv Therapeutics Inc.
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Please enable JavaScript to continue using this application.